JP Morgan Maintains Overweight on Boeing, Lowers Price Target to $188
JP Morgan analyst Seth Seifman maintains Boeing (NYSE:BA) with a Overweight and lowers the price target from $190 to $188.
Susquehanna Maintains Positive on NVIDIA, Lowers Price Target to $220
Susquehanna analyst Christopher Rolland maintains NVIDIA (NASDAQ:NVDA) with a Positive and lowers the price target from $260 to $220.
Deutsche Bank Downgrades Gap to Hold, Lowers Price Target to $9
Deutsche Bank analyst Gabriella Carbone downgrades Gap (NYSE:GPS) from Buy to Hold and lowers the price target from $12 to $9.
Barclays Maintains Overweight on AerCap Holdings, Lowers Price Target to $58
Barclays analyst Mark Devries maintains AerCap Holdings (NYSE:AER) with a Overweight and lowers the price target from $72 to $58.
B of A Securities Downgrades Sherwin-Williams to Neutral, Lowers Price Target to $292
B of A Securities analyst Steve Byrne downgrades Sherwin-Williams (NYSE:SHW) from Buy to Neutral and lowers the price target from $313 to $292.
B of A Securities Initiates Coverage On Enhabit with Underperform Rating, Announces Price Target of $16
B of A Securities analyst Joanna Gajuk initiates coverage on Enhabit (NYSE:EHAB) with a Underperform rating and announces Price Target of $16.
B of A Securities Downgrades Veritone to Neutral, Lowers Price Target to $10
B of A Securities analyst Koji Ikeda downgrades Veritone (NASDAQ:VERI) from Buy to Neutral and lowers the price target from $14 to $10.
Barclays Maintains Overweight on Certara, Lowers Price Target to $24
Barclays analyst Luke Sergott maintains Certara (NASDAQ:CERT) with a Overweight and lowers the price target from $25 to $24.
Baird Downgrades Verra Mobility to Neutral
Baird analyst David Koning downgrades Verra Mobility (NASDAQ:VRRM) from Outperform to Neutral.
Stifel Downgrades Atara Biotherapeutics to Hold, Lowers Price Target to $5
Stifel analyst Benjamin Burnett downgrades Atara Biotherapeutics (NASDAQ:ATRA) from Buy to Hold and lowers the price target from $16 to $5.